News & Media
News Updates
The data from our pharmacokinetic (PK) study shows that fingerprint sweat mimics the rate and extent of codeine in blood and saliva. The study demonstrated that fingerprint sweat provides a
PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW YORK,
Quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of year-on-year growth Higher-margin, recurring cartridge revenue surpassed reader revenue as primary driver Completed in-clinic portion of FDA
Digital Marketing Initiatives to Highlight Innovative Non-Invasive Drug Screening Technology and Market Expansion Plans NEW YORK, October 31, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”),
Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary driver Expanded distribution network in Saudi Arabia NEW YORK, October
Developer Praises Intelligent Bio Solutions’ Innovative Drug Testing Solution for Improving Workplace Safety NEW YORK, October 24, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a
Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and Productivity NEW YORK, October 14, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the
NEW YORK, October 09, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its distribution
New York, October 01, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition
New York, September 27, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful
New York, September 25, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Thanet
Fourth-quarter revenue of $0.73 million, up 64% year-over-year Full-year revenue of $3.11 million, up 148% year-over-year As of June 30, 2024, the Company had $6.30 million in cash NEW YORK,
Media Contact
For media enquiries, please contact marketing@ibs.inc.
Featured Media
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. Our innovative technology has been featured worldwide in leading news outlets and media platforms.
The Intelligent Fingerprinting Drug Screening System is revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.
